Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High-Risk Pregnancy Clear all
Completed No phase listed Observational

Blood Pressure Change and Outcome

NCT01330004
View directory record Official record
Conditions
Renal Disease, High Blood Pressure
Interventions
Not listed
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 88 Years
Enrollment
12,695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jul 22, 2026, 2:05 PM EDT
Completed No phase listed Observational

A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria

NCT05967806
View directory record Official record
Conditions
Renal Disease
Interventions
assessment
Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
2,575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
17
States / cities
Huntsville, Alabama • Bakersfield, California • Chatsworth, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 22, 2026, 2:05 PM EDT
Terminated No phase listed Observational

Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

NCT00579150
View directory record Official record
Conditions
Birth Defects, Type 2 Diabetes, Preterm Birth
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Jul 22, 2026, 2:05 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Sefaxersen (RO7434656), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
40
States / cities
Alabaster, Alabama • Birmingham, Alabama • Surprise, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 2:05 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions
Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
415
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 332 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

NCT04296890
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
34
States / cities
Phoenix, Arizona • Duarte, California • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jul 22, 2026, 2:05 PM EDT
Not listed Phase 1 Interventional

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

NCT00769613
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 22, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Kaiser Permanente Evaluation of Medically Tailored Meals in Adults With Medical Conditions at High Readmission Risk

NCT05166525
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Diseases, Diabetes Mellitus, Type 2
Interventions
Medically tailored meals
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Oakland, California • San Francisco, California • San Rafael, California + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jul 22, 2026, 2:05 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835
View directory record Official record
Conditions
Chronic Kidney Disease With High Proteinuria
Interventions
Zibotentan/Dapagliflozin, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 95 Years
Enrollment
1,835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
64
States / cities
Huntsville, Alabama • Sun City West, Arizona • Bakersfield, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 22, 2026, 2:05 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women

NCT04783558
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Opioid-use Disorder
Interventions
Mobile-based NAS Caregiving Tool
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional

Continuous Glucose Monitor Use in Pregnancy

NCT05317585
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin, Pregnancy, High Risk
Interventions
Continuous Glucose Monitor, Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
Device
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 22, 2026, 2:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT07115043
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
Interventions
AZD6750, rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amniotic Fluid Sludge in Cerclage Patients as an Indicator for Increased Risk of Preterm Delivery and Neonatal Outcome.

NCT00722085
View directory record Official record
Conditions
High Risk Pregnancy, Incompetent Cervix, Cerclage, Amniotic Fluid Sludge, Gestation Age at Delivery.
Interventions
Not listed
Lead sponsor
Center For Maternal Fetal Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Jul 22, 2026, 2:05 PM EDT
Not yet recruiting Not applicable Interventional

Signatera Assessment in Early-Stage Endometrial Cancer

NCT07339384
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Signatera Genome ultra-sensitive ctDNA blood test
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 2:05 PM EDT
Not listed Phase 4 Interventional

Gentamicin Bladder Instillation Trial

NCT01884467
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gentamicin, Placebo
Drug
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Jul 22, 2026, 2:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Use of GnRH Agonist Trigger in the Prevention of OHSS

NCT00349258
View directory record Official record
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
Leuprolide acetate
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
20 Years to 39 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2006 · Synced Jul 22, 2026, 2:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Preeclampsia Registry

NCT06377878
View directory record Official record
Conditions
Preeclampsia, Eclampsia, HELLP Syndrome, Toxemia, Hypertensive Disorder of Pregnancy
Interventions
Not listed
Lead sponsor
Preeclampsia Foundation
Other
Eligibility
13 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2040
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Jul 22, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions

NCT02481414
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
PepCan, Candin®
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Jul 22, 2026, 2:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT04752293
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 22, 2026, 2:05 PM EDT
Active, not recruiting Phase 2 Interventional

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685
View directory record Official record
Conditions
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
35
States / cities
Tucson, Arizona • Fresno, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 22, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer

NCT00003080
View directory record Official record
Conditions
Ovarian Cancer
Interventions
endocrine-modulating drug therapy, melphalan, mitoxantrone hydrochloride, tamoxifen citrate, thiotepa, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Jul 22, 2026, 2:05 PM EDT
Terminated Phase 1 Interventional Results available

MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03585764
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
MOv19-BBz CAR T cells, Alpha Folate Receptor expression test
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jul 22, 2026, 2:05 PM EDT
Active, not recruiting Not applicable Interventional

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

NCT04454450
View directory record Official record
Conditions
Ovarian Cancer, High Grade Ovarian Serous
Interventions
PET/MRI, Contrast enhanced CT
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 2:05 PM EDT
Recruiting Early Phase 1 Interventional

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

NCT05691010
View directory record Official record
Conditions
Endometrial Cancer, Stage III Endometrial Cancer, Stage III Endometrial Carcinoma, Endometrial Carcinoma, Endometrial Carcinoma Stage III
Interventions
Intensity-modulated radiation therapy, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 2:05 PM EDT